Abstract
With the aging of the world population, neurodegenerative diseases are considered crippling diseases, which seriously affect the quality of life and are an increasing burden on society and the economy. As a major alkaloid in Ligusticum chuanxiong Hort, tetramethylpyrazine (TMP) plays an increasingly significant role during neurodegenerative diseases, including roles as an anti-inflammatory, antioxidative, antiplatelet citatory poisoning, and anti-inflammation. This review focuses on the latest advances in the roles and mechanisms of action of TMP in neurodegenerative diseases to stimulate new concepts and methods for the prevention and treatment of neurodegenerative diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cabreira V, Massano J (2019) Parkinson’s disease: clinical review and update. Acta Med Port 32(10):661–670. https://doi.org/10.20344/amp.11978
Cai W, Zhang Y, Liu Y, Liu H, Zhang Z et al (2019) Effects of miR-150 on neuropathic pain process via targeting AKT3. Biochem Biophys Res Commun 517(3):532–537. https://doi.org/10.1016/j.bbrc.2019.07.061
Chen H, Cao J, Zha L, Wang P, Liu Z et al (2020) Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson’s disease models through activating the MEF2-PGC1α and BDNF/CREB pathways. Aging 12(14):14897–14917. https://doi.org/10.18632/aging.103551
Chen H, Cao J, Zhu Z, Zhang G, Shan L et al (2018) A novel tetramethylpyrazine derivative protects against glutamate-induced cytotoxicity through PGC1α/Nrf2 and PI3K/Akt signaling pathways. Front Neurosci 12:567. https://doi.org/10.3389/fnins.2018.00567
Chen H, Tan G, Cao J, Zhang G, Yi P et al (2017) Design, synthesis, and biological evaluation of novel tetramethylpyrazine derivatives as potential neuroprotective agents. Chem Pharm Bull (tokyo) 65(1):56–65. https://doi.org/10.1248/cpb.c16-00699
Chen HY, Xu DP, Tan GL, Cai W, Zhang GX et al (2015) A potent multi-functional neuroprotective derivative of tetramethylpyrazine. J Mol Neurosci 56(4):977–987. https://doi.org/10.1007/s12031-015-0566-x
Collins GA, Goldberg AL (2017) The logic of the 26S proteasome. Cell 169(5):792–806. https://doi.org/10.1016/j.cell.2017.04.023
Cui H, Xu Z, Qu C (2020) Tetramethylpyrazine ameliorates isoflurane-induced cognitive dysfunction by inhibiting neuroinflammation via miR-150 in rats. Exp Ther Med 20(4):3878–3887. https://doi.org/10.3892/etm.2020.9110
Danduga R, Dondapati SR, Kola PK, Grace L, Tadigiri RVB et al (2018) Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington’s disease-like symptoms in rats. Biomed Pharmacother 105:1254–1268. https://doi.org/10.1016/j.biopha.2018.06.079
Erkkinen MG, Kim MO, Geschwind MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol 10(4):a033118. https://doi.org/10.1101/cshperspect.a033118
Gaudet AD, Fonken LK, Watkins LR, Nelson RJ, Popovich PG (2018) MicroRNAs: roles in regulating neuroinflammation. Neuroscientist 24(3):221–245. https://doi.org/10.1177/1073858417721150
Gerrits E, Brouwer N, Kooistra SM, Woodbury ME, Vermeiren Y et al (2021) Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease. Acta Neuropathol 141(5):681–696. https://doi.org/10.1007/s00401-021-02263-w
Guan D, Su Y, Li Y, Wu C, Meng Y, Peng X, Cui Y (2015) Tetramethylpyrazine inhibits CoCl2-induced neurotoxicity through enhancement of Nrf2/GCLc/GSH and suppression of HIF1α/NOX2/ROS pathways. J Neurochem 134(3):551–565. https://doi.org/10.1111/jnc.13161
Guo B, Xu D, Duan H, Du J, Zhang Z et al (2014) Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson’s disease in vitro and in vivo. Biol Pharm Bull 37(2):274–285. https://doi.org/10.1248/bpb.b13-00743
Guo M, Liu Y, Shi D (2016) Cardiovascular actions and therapeutic potential of tetramethylpyrazine (active component isolated from Rhizoma Chuanxiong): roles and mechanisms. Biomed Res Int 2016:2430329. https://doi.org/10.1155/2016/2430329
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141(7):1917–1933. https://doi.org/10.1093/brain/awy132
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17071. https://doi.org/10.1038/nrdp.2017.71
He L, He T, Farrar S, Ji L, Liu T et al (2017) Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem 44(2):532–553. https://doi.org/10.1159/000485089
Hu S, Hu H, Mak S, Cui G, Lee M et al (2018) A novel tetramethylpyrazine derivative prophylactically protects against glutamate-induced excitotoxicity in primary neurons through the blockage of N-methyl-D-aspartate receptor. Front Pharmacol 9:73. https://doi.org/10.3389/fphar.2018.00073
Hu S, Wang L, Mak S, Zhang Z, Xu D et al (2016) Potent protection against MPP(+)-induced neurotoxicity via activating transcription factor MEF2D by a novel derivative of naturally occurring danshensu/tetramethylpyrazine. Neuromolecular Med 18(4):561–572. https://doi.org/10.1007/s12017-016-8399-5
Huang X, Yang J, Huang X, Zhang Z, Liu J et al (2021) Tetramethylpyrazine improves cognitive impairment and modifies the hippocampal proteome in two mouse models of Alzheimer’s disease. Front Cell Dev Biol 9:632843. https://doi.org/10.3389/fcell.2021.632843
Islam MT (2017) Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res 39(1):73–82. https://doi.org/10.1080/01616412.2016.1251711
Ji LJ, Shi J, Lu JM, Huang QM (2018) MiR-150 alleviates neuropathic pain via inhibiting toll-like receptor 5. J Cell Biochem 119(1):1017–1026. https://doi.org/10.1002/jcb.26269
Koutsokera M, Kafkalias P, Giompres P, Kouvelas ED, Mitsacos A (2014) Expression and phosphorylation of glutamate receptor subunits and CaMKII in a mouse model of Parkinsonism. Brain Res 1549:22–31. https://doi.org/10.1016/j.brainres.2013.12.023
Li G, Hong G, Li X, Zhang Y, Xu Z et al (2018) Synthesis and activity towards Alzheimer’s disease in vitro: tacrine, phenolic acid and ligustrazine hybrids. Eur J Med Chem 148:238–254. https://doi.org/10.1016/j.ejmech.2018.01.028
Li G, Liu S, Wang H, Pan R, Tang H et al (2020) Ligustrazine ameliorates lipopolysaccharide-induced neurocognitive impairment by activating autophagy via the PI3K/AKT/mTOR pathway. Int J Mol Med 45(6):1711–1720. https://doi.org/10.3892/ijmm.2020.4548
Liu CA, Zhu J, Cai B, Huang JL (2014) Tetramethylpyrazine protect rats against the inflammation and Aβ25-35 induced ROS by targeting the RAGE-ERK1/2-p38-NFκB pathway. Chin Pharm J 49(13):1126–1132
Lu C, Zhang J, Shi X, Miao S, Bi L et al (2014) Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson’s disease induced by MPTP. Int J Biol Sci 10(4):350–357. https://doi.org/10.7150/ijbs.8366
Lu F, Li X, Li W, Wei K, Yao Y et al (2017) Tetramethylpyrazine reverses intracerebroventricular streptozotocin-induced memory deficits by inhibiting GSK-3β. Acta Biochim Biophys Sin (shanghai) 49(8):722–728. https://doi.org/10.1093/abbs/gmx059
Luo X, Yu Y, Xiang Z, Wu H, Ramakrishna S et al (2017) Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity. J Neurochem 141(3):373–386. https://doi.org/10.1111/jnc.13970
McColgan P, Tabrizi SJ (2018) Huntington’s disease: a clinical review. Eur J Neurol 25(1):24–34. https://doi.org/10.1111/ene.13413
Meng D, Lu H, Huang S, Wei M, Ding P et al (2014) Comparative pharmacokinetics of tetramethylpyrazine phosphate in rat plasma and extracellular fluid of brain after intranasal, intragastric and intravenous administration. Acta Pharm Sin B 4(1):74–78. https://doi.org/10.1016/j.apsb.2013.12.009
Michel HE, Tadros MG, Esmat A, Khalifa AE, Abdel-Tawab AM (2017) Tetramethylpyrazine ameliorates rotenone-induced Parkinson’s disease in rats: involvement of its anti-inflammatory and anti-apoptotic actions. Mol Neurobiol 54(7):4866–4878. https://doi.org/10.1007/s12035-016-0028-7
Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ et al (2018) Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease. J Neuroinflammation 15(1):276. https://doi.org/10.1186/s12974-018-1313-3
Pajares M, A IR, Manda G, Boscá L, Cuadrado A (2020) Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells 9(7):1687. https://doi.org/10.3390/cells9071687
Razgonova MP, Veselov VV, Zakharenko AM, Golokhvast KS, Nosyrev AE et al (2019) Panax ginseng components and the pathogenesis of Alzheimer’s disease (Review). Mol Med Rep 19(4):2975–2998. https://doi.org/10.3892/mmr.2019.9972
Shao Z, Wu P, Wang X, Jin M, Liu S et al (2018) Tetramethylpyrazine protects against early brain injury and inhibits the PERK/Akt pathway in a rat model of subarachnoid hemorrhage. Neurochem Res 43(8):1650–1659. https://doi.org/10.1007/s11064-018-2581-0
Shi J, Wang Y, Luo G (2012) Ligustrazine phosphate ethosomes for treatment of Alzheimer’s disease, in vitro and in animal model studies. AAPS PharmSciTech 13(2):485–492. https://doi.org/10.1208/s12249-012-9767-6
Shoshan-Barmatz V, Nahon-Crystal E, Shteinfer-Kuzmine A, Gupta R (2018) VDAC1, mitochondrial dysfunction, and Alzheimer’s disease. Pharmacol Res 131:87–101. https://doi.org/10.1016/j.phrs.2018.03.010
Singh A, Kukreti R, Saso L (2019) Oxidative stress: a key modulator in neurodegenerative diseases. Molecules 24(8):1583. https://doi.org/10.3390/molecules24081583
Song A, Yi Q, Zhu M (2015) Study of the therapeutic effect of ligustrazine injection add-on therapy on Parkinson’s disease. Stroke and Nervous Diseases 22(01):25–27
Sun XJ, Cun-Ling Z, Xiao YM, Neurology DO, Hospital ZP (2016) Observation on clinical curative effect of ligustrazine addition in treatment of Parkinson’s disease. China Foreign Med Treatment 35(12):138–139+147. https://doi.org/10.16662/j.cnki.1674-0742.2016.12.138 (in chinese)
Wang LY, Yu X, Li XX, Zhao YN, Wang CY et al (2019a) Catalpol exerts a neuroprotective effect in the MPTP mouse model of Parkinson’s disease. Front Aging Neurosci 11:316. https://doi.org/10.3389/fnagi.2019.00316
Wang N, Yang W, Li L, Tian M (2020) MEF2D upregulation protects neurons from oxygen-glucose deprivation/re-oxygenation-induced injury by enhancing Nrf2 activation. Brain Res 1741:146878. https://doi.org/10.1016/j.brainres.2020.146878
Wang R, Reddy PH (2017) Role of glutamate and NMDA receptors in Alzheimer’s disease. J Alzheimers Dis 57(4):1041–1048. https://doi.org/10.3233/jad-160763
Wang S, Xia B, Qiao Z, Duan L, Wang G et al (2019b) Tetramethylpyrazine attenuated bupivacaine-induced neurotoxicity in SH-SY5Y cells through regulating apoptosis, autophagy and oxidative damage. Drug Des Devel Ther 13:1187–1196. https://doi.org/10.2147/dddt.s196172
Wen J, Li S, Zheng C, Wang F, Luo Y et al (2021) Tetramethylpyrazine nitrone improves motor dysfunction and pathological manifestations by activating the PGC-1α/Nrf2/HO-1 pathway in ALS mice. Neuropharmacology 182:108380. https://doi.org/10.1016/j.neuropharm.2020.108380
Wen M, Zhou B, Wang Y, Anatomy DO, University GM (2013) Effect of tetramethy lpyrazine-administration on tyrosine hydroxylase in midbrain of Parkinson disease mice model. Chin J Gerontol 33(17):4173–4175
Wu W, Liang X, Xie G, Chen L, Liu W et al (2018) Synthesis and evaluation of novel ligustrazine derivatives as multi-targeted inhibitors for the treatment of Alzheimer’s disease. Molecules 23(10):2540. https://doi.org/10.3390/molecules23102540
Wu W, Zhang Z, Li F, Deng Y, Lei M (2020) A network-based approach to explore the mechanisms of Uncaria alkaloids in treating hypertension and alleviating Alzheimer’s disease. Int J Mol Sci 21(5):1766. https://doi.org/10.3390/ijms21051766
Xu LT (2019) Analysis of the efficacy of Danshen ligustrazine combined with pramipexole in the treatment of vascular Parkinson’s syndrome. Chinese Medical Science 9(12):44–46 (in chinese)
Yang A, Liu C, Wu J, Kou X, Shen R (2021) A review on α-mangostin as a potential multi-target-directed ligand for Alzheimer’s disease. Eur J Pharmacol 897:173950. https://doi.org/10.1016/j.ejphar.2021.173950
Yin SJ, Zhang T, Tong GY, Song QJ, Wang Y et al (2016) Effects of ligustrazine on learning memory capacity and expression of cell cycle protein E and P21 in rats with Alzheimer’s disease. Chinese Gerontology 36(020):4961–4962 (in chinese)
Younes I, Rinaudo M (2015) Chitin and chitosan preparation from marine sources. Structure, properties and applications. Mar Drugs 13(3):1133–1174. https://doi.org/10.3390/md13031133
Yu L, Wu AG, Wong VK, Qu LQ, Zhang N et al (2019) The new application of UHPLC-DAD-TOF/MS in identification of inhibitors on β-amyloid fibrillation from Scutellaria baicalensis. Front Pharmacol 10:194. https://doi.org/10.3389/fphar.2019.00194
Zhang G, Wu J, Huang C, Cheng J, Su Z et al (2021) The tetramethylpyrazine analogue T-006 alleviates cognitive deficits by inhibition of tau expression and phosphorylation in transgenic mice modeling Alzheimer’s disease. J Mol Neurosci 71(7):1456–1466. https://doi.org/10.1007/s12031-020-01762-x
Zhang H, Sun R, Liu XY, Shi XM, Wang WF et al (2014) A tetramethylpyrazine piperazine derivate CXC137 prevents cell injury in SH-SY5Y cells and improves memory dysfunction of rats with vascular dementia. Neurochem Res 39(2):276–286. https://doi.org/10.1007/s11064-013-1219-5
Zhang X, Hu H, Luo J, Deng H, Yu P et al (2017) A novel danshensu-tetramethylpyrazine conjugate DT-010 provides cardioprotection through the PGC-1α/Nrf2/HO-1 pathway. Biol Pharm Bull 40(9):1490–1498. https://doi.org/10.1248/bpb.b17-00313
Zhao C, Lv Y, Cui H, Zhu Y, Wei M et al (2021) Phase I safety, tolerability, and pharmacokinetic studies of tetramethylpyrazine nitrone in healthy Chinese volunteers. Drug Dev Res 82(1):97–107. https://doi.org/10.1002/ddr.21733
Zhao H, Xu ML, Zhang Q, Guo ZH, Peng Y et al (2014) Tetramethylpyrazine alleviated cytokine synthesis and dopamine deficit and improved motor dysfunction in the mice model of Parkinson’s disease. Neurol Sci 35(12):1963–1967. https://doi.org/10.1007/s10072-014-1871-9
Zhou H, Shao M, Guo B, Li C, Lu Y et al (2019a) Tetramethylpyrazine analogue T-006 promotes the clearance of alpha-synuclein by enhancing proteasome activity in Parkinson’s disease models. Neurotherapeutics 16(4):1225–1236. https://doi.org/10.1007/s13311-019-00759-8
Zhou H, Shao M, Yang X, Li C, Cui G et al (2019b) Tetramethylpyrazine analogue T-006 exerts neuroprotective effects against 6-hydroxydopamine-induced Parkinson’s disease in vitro and in vivo. Oxid Med Cell Longev 2019:8169125. https://doi.org/10.1155/2019/8169125
Zhu JX (2007) Literature analysis of adverse reactions to ligustrazine injection. China Practical Medicine 003(003):38–40 (in Chinese)
Acknowledgements
This work was supported by the Project of Shanghai Science and Technology Commission (19401970600) and the Project of Shanghai Science and Technology Commission (19401932500), and Shanghai will further accelerate the 3-year action plan for the development of TCM (2018–2020) for major clinical research on TCM (ZY (2018–2020)-CCCX-4010), the Innovation Fund of Integrated Traditional Chinese and Western Medicine, School of Medicine, Shanghai Jiao Tong University (18zxy002), the 2019 Teacher Training and Development Project of Medical School of Shanghai Jiao Tong University (JFXM201909), and the Experimental Project of Scientific and Technological Innovation for College Students of Heilongjiang University of Traditional Chinese Medicine.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Meng, Z., Chen, H. & Meng, S. The Roles of Tetramethylpyrazine During Neurodegenerative Disease. Neurotox Res 39, 1665–1677 (2021). https://doi.org/10.1007/s12640-021-00398-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-021-00398-y